R Squared Ltd Acquires Shares of 110 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

R Squared Ltd bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 110 shares of the pharmaceutical company’s stock, valued at approximately $44,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in VRTX. Czech National Bank increased its stake in Vertex Pharmaceuticals by 6.2% during the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after acquiring an additional 3,260 shares during the period. Whalen Wealth Management Inc. bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth $662,000. Mizuho Securities USA LLC raised its stake in Vertex Pharmaceuticals by 289.0% in the third quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after purchasing an additional 57,497 shares in the last quarter. Nordea Investment Management AB lifted its position in Vertex Pharmaceuticals by 19.4% during the fourth quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock worth $137,783,000 after purchasing an additional 55,739 shares during the period. Finally, Keynote Financial Services LLC acquired a new stake in Vertex Pharmaceuticals during the third quarter worth about $498,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

VRTX has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a report on Friday. Scotiabank upped their target price on Vertex Pharmaceuticals from $430.00 to $433.00 and gave the stock a “sector perform” rating in a research note on Friday. StockNews.com lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 21st. Wells Fargo & Company downgraded Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price objective for the company. in a research report on Thursday. Finally, Truist Financial decreased their target price on Vertex Pharmaceuticals from $550.00 to $460.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Stock Up 5.3 %

Shares of NASDAQ VRTX opened at $461.68 on Monday. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The company’s 50 day moving average price is $434.55 and its 200-day moving average price is $462.93. The company has a market capitalization of $118.90 billion, a P/E ratio of -232.00, a price-to-earnings-growth ratio of 2.29 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same period last year, the business posted $3.67 EPS. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.